Daiichi Sankyo Company, Limited (DSKYF)
| Market Cap | 31.58B -21.6% |
| Revenue (ttm) | 13.35B +12.6% |
| Net Income | 1.63B -12.1% |
| EPS | 0.88 -9.9% |
| Shares Out | n/a |
| PE Ratio | 19.32 |
| Forward PE | n/a |
| Dividend | 0.51 (2.97%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 1,500 |
| Average Volume | 6,025 |
| Open | 16.80 |
| Previous Close | 17.10 |
| Day's Range | 16.80 - 17.20 |
| 52-Week Range | 15.16 - 29.15 |
| Beta | -0.18 |
| RSI | 49.57 |
| Earnings Date | May 11, 2026 |
About Daiichi Sankyo Company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment ... [Read more]
Financial Performance
In fiscal year 2026, Daiichi Sankyo Company's revenue was 2.12 trillion, an increase of 12.55% compared to the previous year's 1.89 trillion. Earnings were 259.87 billion, a decrease of -12.13%.
Financial numbers in JPY Financial StatementsNews
Daiichi Sankyo Company Earnings Call Transcript: Q4 2026
FY 2025 saw double-digit revenue growth led by oncology, but operating profit declined due to one-time costs. The new five-year plan targets over JPY 3 trillion revenue by FY 2030, with continued focus on oncology, R&D investment, and progressive dividends.
Daiichi Sankyo Earnings Fall; Guides FY27
(RTTNews) - Daiichi Sankyo Co. Ltd. (DSKYF, 4568.T, DSNKY), a Japanese pharmaceutical company, on Monday reported lower net income in the full year ended March 31, 2026 compared with the previous year...
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in oncolo...
Daiichi Sankyo Company Transcript: Investor update
Operating profit forecast for FY 2025 was cut by JPY 106 billion due to temporary expenses from revised ADC supply plans and CMO compensation. The company is shifting to a risk-adjusted supply strategy, optimizing in-house and CMO roles, and maintaining its dividend outlook.
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital p...
Fortis Healthcare awaits Tokyo court judgement in NTK's claim against Daiichi Sankyo
Fortis Healthcare Limited has announced that the Tokyo District Court has concluded the preparatory and oral proceedings in the litigation filed by Northern TK Venture Pte Ltd (NTK) against Daiichi…
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies
PETACH TIKVA, Israel, April 16, 2026 /PRNewswire/ -- Interna Therapeutics, a clinical stage biotechnology company advancing its Molecular Nano Motor (MNM) intracellular delivery platform, today announ...
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase
SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today announced the advancement to the sec...
4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program
NEWTON, Mass.--(BUSINESS WIRE)-- #4DPath--4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program.
Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs
SAN DIEGO--(BUSINESS WIRE)--Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics using its proprietary PrimeBody platform, today announced a research collaboration with Daii...
Nikkei Rises 1.1%, Led by Shipping, Financial Stocks
Japanese stocks were broadly higher as overnight declines in crude oil prices ease fears about energy costs amid the Middle East conflict.
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
HAMBURG, Germany & MUNICH--(BUSINESS WIRE)--GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
SylamoreBio Announces Research Collaboration With Daiichi Sankyo to Advance SyLEC™ Delivery Technology
JONESBORO, Ark.--(BUSINESS WIRE)--SylamoreBio, a biotechnology company pioneering advanced therapeutic delivery to the central nervous system (CNS) and other recalcitrant tissues, today announced it h...
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effectiv...
BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568). T...
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma...
Daiichi Sankyo Company Earnings Call Transcript: Q3 2026
Revenue rose 12.1% year-on-year, led by ENHERTU and DATROWAY, with core operating profit up 8.8%. Oncology sales drove growth, while operating profit was impacted by one-time costs. No change to full-year guidance; focus remains on expanding key drug indications and managing generic competition.
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen ...
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines TORONTO, Jan. 21, 2026 /PRNewswire/ - Daiichi Sankyo (TSE: 4568) has further...
Daiichi Sankyo Company Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant growth was achieved through a strategic shift to oncology, led by ENHERTU and DATROWAY, with robust financial performance and global expansion. The company is advancing its ADC platform, expanding indications, and investing in next-generation technologies for sustained growth.
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio.
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe.
Daiichi Sankyo Company Transcript: Status Update
The event highlighted robust growth in the oncology pipeline, with multiple new ADC approvals, strong market uptake, and a focus on expanding manufacturing and research platforms. Strategic initiatives aim for global leadership in oncology by 2030, supported by innovation in ADCs, immuno-oncology, and supply chain expansion.
US FDA approves Daiichi Sankyo's therapy to treat breast cancer
The U.S. Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line treatment of patients with a type of breast cancer, the regulator said o...
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea , Dec. 15, 202...